used to select predictors, where the best fitting model is the one that minimizes the deviance in cross-validation. RESULTS: Over an average follow-up of 6 years, 635 individuals developed PAD. The hazard ratios for selected risk factors in the predictive models are presented in below table. The final model 2 was significantly (P<0.001) more accurate than the model 1 that included age, sex, race, and ABI. CONCLUSIONS: A model using readily available clinical and laboratory tests can improve discrimination over ABI between those CKD patients who will and those who will not develop PAD. Further studies should validate this predictive model. MP382 DISEASE KNOWLEDGE AND INFORMATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE, CKDREIN COHORT Carole Ayav 1 , Karine Legrand 1 , Be ´ ne ´ dicte Stengel 3 , Luc Frimat 2 , Serge Brianc ¸on 1 1 CIC 1433 Epide ´miologie Clinique, Inserm CHRU Nancy Vandoeuvre les Nancy France, 2 Nephrology Department CHRU Nancy Vandoeuvre les Nancy France and 3  Equipe 5,  Epide ´miologie Re ´nale et Cardiovasculaire, Inserm U1018 Inserm Villejuif France INTRODUCTION AND AIMS: Because of the medical and socio-economic burden of chronic kidney disease (CKD), improved patient empowerment is expected. The improvement of the patient’s knowledge and disease understanding can allow this empowerment, but remains poorly documented. CKD REIN cohort will be able to highlight this question. Our aim was to assess the level of patient’s CKD knowledge, information or therapeutic educational status and their determinants. METHODS: The national CKD REIN cohort included a representative sample of 3000 CKD patients followed-up in nephrology departments. The patients received a self- administered questionnaire and have been interviewed at baseline and during the 5 years of follow-up. The inclusion data was used. Among the CKD REIN cohort patients, 2679 had responded to baseline questionnaire and interview and could be included in the analysis. The determinants have been explored, using logistic regression model. RESULTS: Patients mean age was 67.2 yrs; 65.7% were men; 55.2% were in CKD stage 3, 40.8% in stage 4 and 4% in stage 5; mean length of CKD was 8.1 yrs. 90% were able to date the beginning of CKD, 35.2% admitted to know their CKD stage, agreement between declared and measured stage was 0.65 (Kappa coefficient). One quarter declared having received proposition to participate in information or educational sessions about CKD and only 13% in renal treatment options and 12% in renal prevention. Less than 30% declared having discussed treatment options with their practitioner and 34.5% having made their choice. The exploration of determinants showed that age at CKD diagnosis (per 10yrs OR=0.2); Diploma; diabetes (OR=0.7); length of CKD and “patient’s expectations answer” (OR=1.6) were associated with the patient’s CKD stage knowledge. Stage of CKD (stage 3 OR=1, stage 4 OR=2.1, stage 5 OR=3.0), quality of information (OR=3.5) and “patient’s expectations answer” (OR=2.6) were associated with the participation in an educational program. Finally factors associated with the patient choice of treatment options were: sex (women OR=0.8); age at diagnosis (OR=0.5 after 35yrs); stage of CKD (stage 3 OR=1, stage 4 OR=2, stage 5 OR=6); quality of information (OR=1.9) and “patient’s expectations answer” (OR=1.6). CONCLUSIONS: These primary findings show that patient CKD knowledge and information are weak, and the educational program proposition is uncommon. Therapeutic educational program allow patients to improve their disease understanding and their compliance, reduce complications and slow disease progression. The choice of treatment option by the patient should improve the transition to end-stage renal disease, reduce complications during this step and improve quality of life and satisfaction with care. Some of factors associated with information, educational program and patient’s treatment choice are modifiable. So we need to improve and to promote information and educational program in primary care and nephrology departments. MP383 EFFECTS OF INTENSIVE BLOOD PRESSURE LOWERING ON KIDNEY DISEASE PROGRESSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS Hon-Yen Wu 3,1,2 , Wan-Chuan Tsai 1,2 , Yu-Sen Peng 1,3 , Kuan-Yu Hung 3 , Kuo- Liong Chien 2,3 1 Internal Medicine Far Eastern Memorial Hospital New Taipei City Taiwan, 2 Institute of Epidemiology and Preventive Medicine National Taiwan University College of Public Health Taipei City Taiwan and 3 Internal Medicine National Taiwan University Hospital and College of Medicine Taipei City Taiwan INTRODUCTION AND AIMS: Development and progression of chronic kidney disease (CKD) are closely inter-related to hypertension, and strict blood pressure (BP) control is able to decrease the risk of decline in renal function. However, the intensive BP lowering strategy and the optimal BP target remain debated. This study aimed to compare intensive BP lowering treatments (target < 130/80 mmHg) with standard BP lowering treatments (target < 140/90 mmHg) on kidney disease progression in CKD patients without diabetes. METHODS: We searched PubMed, MEDLINE, Embase, and Cochrane Library up to March, 2016. Eligible studies should be randomized clinical trials that compared an intensive BP lowering treatment with a standard BP lowering treatment in nondiabetic adults with CKD, and reported the change in glomerular filtration rate (GFR). We used random-effects meta-analyses for pooling effect measures. The difference in annual rate of change in GFR was expressed as mean difference (MD) with 95% confidence interval (CI). RESULTS: We identified 8 studies with 7400 patients. Compared with standard BP lowering treatments, intensive BP lowering treatments did not show a significant difference on the annual rate of change in GFR (MD 0.07, 95% CI -0.16 to 0.29 ml/ min/1.73 m 2 /year; Figure 1). Meta-regression showed a trend of lower risk in kidney disease progression among non-Blacks (P = 0.09). CONCLUSIONS: Targeting BP below the current standard provides similar renoprotective effects in nondiabetic CKD patients during a timeframe of 3 years. However, patients with non-Black ethnicity might benefit from the intensive BP lower- ing treatments. MP384 WHICH CKD STAGE 3 PATIENTS SHOULD BE REFERRED TO A NEPHROLOGIST? RESULTS OF A RETROSPECTIVE, PATIENT-LEVEL, COHORT ANALYSIS Luis Falc~ ao 1 , Sara Fernandes 1 ,M ario Raimundo 1 , Ana Costa 1 , Catarina Teixeira 1 , S onia Silva 1 , Edgar de Almeida 1 1 Nephrology Hospital Beatriz Angelo Loures Portugal INTRODUCTION AND AIMS: The high prevalence of CKD and its increasing awareness by primary care clinicians is posing a huge burden over health care systems, especially over Nephrology departments. While the referral of CKD stage 4 and 5 to a nephrology clinic is undisputable, the need for stage 3 patients referral is still subject to debate. Our objective was to investigate baseline characteristics of CKD stage 3 patients Abstracts Nephrology Dialysis Transplantation iii568 | Abstracts Downloaded from https://academic.oup.com/ndt/article/32/suppl_3/iii568/3854164 by guest on 31 March 2023